Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

作者：Jing Yuan, Xi-Wen Bi, Xin Hua, Heng Huang, Cai Li, Li Zhao, Qianjun Chen, Xin Chen, Xulin Wang, Ying Lin, An-Qing Zhang, Yong-Yi Zhong, Fei Xu, Jiajia Huang, Xin An, Yan-Xia Shi, Xi Wang, Shu-Sen Wang, Cong Xue, Zhong-Yu Yuan · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00545-5 · 被引用次数：5 · 研究领域：Breast Cancer Treatment Studies、Cancer Treatment and Pharmacology、PARP inhibition in cancer therapy